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Abstract
Variants associated with meconium ileus in cystic fibrosis (CF) were identified in 3,763 patients 
by GWAS. Five SNPs at two loci near SLC6A14 (min P=1.28×10−12 at rs3788766), chr Xq23-24 
and SLC26A9 (min P=9.88×10−9 at rs4077468), chr 1q32.1 accounted for ~5% of the phenotypic 
variability, and were replicated in an independent patient collection (n=2,372; P=0.001 and 0.0001 
respectively). By incorporating that disease-causing mutations in CFTR alter electrolyte and fluid 
flux across epithelia into an hypothesis-driven genome-wide analysis (GWAS-HD), we identified 
the same SLC6A14 and SLC26A9 associated SNPs, while establishing evidence for the 
involvement of SNPs in a third solute carrier gene, SLC9A3. In addition, GWAS-HD provided 
evidence of association between meconium ileus and multiple constituents of the apical plasma 
membrane where CFTR resides (P=0.0002, testing 155 apical genes jointly and replicated, 
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P=0.022). These findings suggest that modulating activities of apical membrane constituents could 
complement current therapeutic paradigms for cystic fibrosis.
Cystic fibrosis is caused by mutations in the cystic fibrosis transmembrane conductance 
regulator (CFTR) gene1. CFTR is a chloride channel located on the apical membrane of 
epithelia, where ion conduction and solute trafficking contribute to the regulation of 
transepithelial fluid flow. Individuals with the same loss-of-function CFTR mutations have 
variable disease severity, and differentially affected CF-associated organs including lung, 
pancreas, liver, intestines, and vas deferens; thus additional features, including other genes 
(referred to as modifier genes) may affect disease pathophysiology. Approximately 15% of 
CF patients have severe intestinal obstruction at birth, a complication known as meconium 
ileus2. Meconium ileus develops in utero, and presents following birth with complete 
intestinal obstruction that requires either medical or surgical intervention. This neonatal 
complication is highly indicative of CF, occurs in either sex, displays notable heritability 
exceeding 88%3, and is likely minimally affected by environmental influences.
The North American CF Gene Modifier Consortium has accumulated 3,763 participants 
with ‘severe’ (pancreatic exocrine insufficient) CFTR alleles and genome-wide genotype 
data at 543,927 SNP loci4,5 (Table 1 and Online Methods). The definition of meconium 
ileus was consistent within the consortium and was recorded following rigorous chart 
review. A conventional GWAS for meconium ileus used a generalized estimating equations 
(GEE) model6 to include collected sibling-pairs, and led to five genome-wide significant 
SNPs (P<5×10−8)7 from two regions that include SLC26A9 on chromosome 1 and SLC6A14 
on chromosome X (Fig. 1, Supplementary Fig. 1, Table 2; sex-specific results in 
Supplementary Table 1). CFTR was not a significant confounder or effect modifier when 
incorporated in the GWAS (Supplementary Fig. 2 and Supplementary Table 2), indicating 
SLC6A14 and SLC26A9 are independent contributors to meconium ileus. We then replicated 
the associations in SLC6A14 (min P=0.001) and SLC26A9 (min P=0.0001) with meconium 
ileus in an independent combined collection from North America and France (Table 2).
The signal intensity plots of the associated SNPs reflected autosomal- and X-associated 
SNPs at SLC26A9 and SLC6A14, respectively. Imputation analysis using MACH and 
minimac8,9 identified the same regions of association as the genotyped SNPs (Online 
Methods, Supplementary Fig. 3). The five associated SNPs in SLC6A14 and two in 
SLC26A9 (Fig. 1b and 1c) are positioned just upstream of their respective transcription start 
sites such that binding of activating or repressing transcription factors may be affected as 
highlighted by ENCODE data10 (data not shown). Neither SLC6A14 nor SLC26A9 coding 
regions exhibit evidence for CNVs; however, there is a gap in the reference sequence >10 kb 
upstream of the SLC26A9 locus.
The seven SNPs genotyped (Table 2) in the two genes account for <5% of the meconium 
ileus variation, estimated by pseudo R-squared11, likely reflecting the common problems in 
association studies of locus heterogeneity and low power given the available sample size. 
Whereas conventional GWAS is often considered for complex disease mapping, modifier 
gene studies could incorporate disease etiology and pathobiology information to increase 
power and account for heterogeneity. To do so, we proposed application of GWAS with 
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consideration of a hypothesis (and so is hypothesis-driven; GWAS-HD) to systematically 
prioritize SNPs for genome-wide analysis. The highest priority markers are also evaluated as 
a set to test the statistical significance of the hypothesis used for prioritization 
(Supplementary Fig. 4).
The GWAS-HD prioritization in this CF application is based on the knowledge that a major 
source of CF pathophysiology is impaired fluid and electrolyte flux in epithelia of CF-
affected organs. The polarized epithelial layer forms a highly selective barrier between 
organ and ductal interfaces. Transepithelial ‘function’ is achieved by cell polarization 
whereby many determinants and regulators of fluid, solute and ion transport reside at the 
apical membrane alongside CFTR, with contributing features from basolateral surfaces. We 
have shown in a mouse model that CFTR function in the gastrointestinal epithelium is 
critical for preventing intestinal obstructions12. Thus, we hypothesized that with loss of 
CFTR, (genetic) variation in other apical membrane constituents could modify CF 
phenotypes, such as meconium ileus.
A list of 157 gene products (Fig. 2 and Supplementary Table 3) was annotated as localized 
to the apical plasma membrane using AmiGO13 with Gene Ontology data14,15. CFTR and 
many solute transporters were included. However, the brush border membrane protein 
SLC6A14 was not listed, reflecting the high specialization of its corresponding intestinal 
cavity and a limitation of the GO annotation that we accepted without additional curation to 
avoid bias. In total, 3,814 GWAS SNPs were within ±10 kb of the boundaries of 155 genes 
(NCBI36/hg18); 2 genes were not tagged by any of the GWAS SNPs.
To implement the GWAS-HD for meconium ileus using the apical hypothesis, we first 
prioritized the genome-wide markers by assigning the 3,814 SNPs of the apical genes to a 
high priority group and all remaining genome-wide SNPs to a low priority group. We then 
performed two statistical analyses (Supplementary Fig. 4 and Online Methods). The first, 
analogous to a conventional GWAS, was to conduct single-SNP association analysis using 
all of the 543,927 GWAS SNPs at the genome-wide level, however after up-weighting the 
3,814 apical SNPs via the SFDR control.16 The second analysis, focusing only on the 3,814 
high priority SNPs using a multi-SNP/gene analysis, tested the prioritization hypothesis 
itself to determine if multiple proteins present on the apical plasma membrane contribute to 
meconium ileus susceptibility.
As in the conventional GWAS, SNPs from SLC6A14 showed the strongest evidence for 
association with meconium ileus in the single-SNP GWAS-HD analysis (Supplementary 
Fig. 5), despite not being in the high priority group, reflecting the robustness of SFDR17. In 
addition, SNPs from SLC26A9, and two additional apical genes, ATP2B2 and SLC9A3, 
showed association evidence with q values <0.05 (Table 3). A gene-based analysis (Online 
Methods) of ATP2B2 (P=0.0006) and SLC9A3 (P=0.0001) indicated evidence for allelic 
heterogeneity after comparing results with single-SNP analysis (Table 3). SLC9A3 was 
replicated in the French cohort (P=0.017) while ATP2B2 was not (P=0.283) 
(Supplementary Table 3).
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Next, restricting analysis to the 3,814 SNPs annotated to the 155 apical genes (which does 
not include SLC6A14), we tested the apical prioritization hypothesis as part of the GWAS-
HD. Here we observed genome-wide significant evidence for association between 
meconium ileus and multiple constituents of the apical plasma membrane (permutation 
P=0.0002, testing all 3,814 SNPs jointly and not subject to multiple hypothesis testing (Fig. 
2a and 2b)). Even with the exclusion of SLC26A9 (as well as SLC6A14), the apical 
hypothesis remained significant (P=0.0058). Thus, GWAS-HD further established the 
involvement of other genes coding for apical constituents despite insufficient power to 
detect individual SNPs, even within the context of our prioritized GWAS. For comparison, 
we also constructed a null hypothesis list of membrane-localized genes. As expected, the 
224 GO-annotated nuclear envelope genes tagged by 3,537 GWAS SNPs showed no 
relationship with meconium ileus (permutation P=0.4639; Fig. 3).
The French cohort with genome-wide data provided independent validation of the apical 
hypothesis (permutation P=0.022; Fig. 2c and 2d; Online Methods). The statistical 
significance of this gene set (which excludes SLC6A14) in the French cohort remained after 
further excluding SLC26A9 (P=0.021) and then both SLC26A9 and SLC9A3 (P=0.023). 
Although analysis of the apical hypothesis in a larger independent cohort should be 
considered as part of future efforts, the replication in the smaller French cohort supports a 
(common) mechanism of contributing genes, even though the responsible gene variants 
across the two datasets may not be the same.
To determine which apical genes were driving the association, the degree of genetic 
heterogeneity in meconium ileus, and the common contributors across the French and North 
American samples, we implemented Lasso18. Using the North American sample, we jointly 
analyzed all 3,740 SNPs available in the apical genes (which include SLC26A9 and 
SLC9A3), and SLC6A14 (Online Methods), that were not in perfect linkage disequilibrium. 
Forty-eight SNPs spanning 36 different genes were retained by Lasso in the multivariate 
regression model (Supplementary Table 3). These SNPs jointly explained ~17% of the 
meconium ileus variation in the North American sample. The percentage explained by the 
same 48 SNPs in the French sample was 8.1% (Online Methods), presumably due to the 
smaller sample size and genetic heterogeneity. We then tested the significance of a score for 
each individual in the French cohort constructed from a weighted sum of the number of risk 
alleles (defined in the North American sample) across the 48 SNPs19. The significant 
association between meconium ileus and this score (P=0.0137; Online Methods) provided 
additional complimentary evidence of common contributors between the two cohorts, with 
SNPs in SLC9A3 and SLC6A14 being two specific examples.
In summary, conventional GWAS identified SNPs in SLC6A14 and SLC26A9 as 
significantly associated with meconium ileus. GWAS-HD single-SNP analysis identified the 
same SNPs in SLC6A14 and SLC26A9, as well as SNPs in SLC9A3; and multi-SNP analysis 
provided evidence that multiple constituents of the apical plasma membrane are collectively 
associated with meconium ileus, yielding considerable additional information beyond single 
SNP/gene associations. GWAS-HD can be applied to other Mendelian disorders, or even 
complex traits provided there is a biologically-based hypothesis and participating relevant 
genes can be compiled.
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Although gene prioritization has been used in other approaches such as pathway or gene 
enrichment analyses20–22, GWAS-HD involves key differences. First, in contrast to the 
previous inclusion/exclusion approaches where all genotyped SNPs/genes are not analyzed 
simultaneously, GWAS-HD performs parallel single-SNP analysis of all GWAS SNPs, and 
multi-SNP/gene analysis focusing on the set of SNPs/genes of interest. The prioritized 
single-SNP analysis interrogates all available SNPs via the SFDR control, yet enables 
increased statistical power for regions favoured a priori. For example, SLC6A14 would be 
omitted by inclusion/exclusion approaches, yet it remained the highest ranked gene for 
association with meconium ileus in GWAS-HD. Second, methods such as interactive 
pathway analysis can be restrictive because contributing genes/proteins must relate to each 
other via direct or indirect links, which may be disturbed when a cog component (such as 
CFTR) is dysfunctional in the disease state. While gene products that participate in 
maturation or delivery of CFTR may be contributory, consideration of local components of 
processes that may compensate for the ion and fluid flow disturbance in CF is enabled in the 
apical hypothesis. Third, distinct from an exhaustive search of all plausible interactive 
pathways, GWAS-HD focuses on a single biological hypothesis and provides statistical 
significance for all genes involved jointly, alleviating the multiple testing burden.
It should be noted that the specific statistics or models used in our GWAS-HD application 
such as SFDR, Lasso, and the sum and score statistics may not be the most powerful ones in 
any specific setting. For example, the adaptive rank truncated product statistic23 could be 
used to identify the common subset of associated apical genes across two samples; and there 
are alternative weighting and prioritization approaches24.
The SLC9A3 gene codes for a sodium/hydrogen exchanger that when disrupted has been 
shown to decrease intestinal obstructions in a CF mouse model25. SLC6A14 codes for a 
sodium- and chloride-dependant neutral and basic amino acid transporter26,27. SLC26A9 
encodes an anion transporter, likely a chloride channel with multiple modes that include 
chloride/bicarbonate exchanger and sodium-anion cotransporter capabilities28. It has also 
been reported to physically interact with CFTR29 and be influenced by CFTR activity, at 
least in lung-related tissues30.
It is notable that SLC9A3 has previously been associated with infections and pulmonary 
function in CF31. In the consortium discovery sample, rs6864158 (MAF=0.43) in SLC9A3 
was associated with both the lung (P=0.0003, analyzed previously5) and meconium ileus 
(P=0.0001); this provides evidence that some genes may play a role in multiple CF co-
morbidities. Both SLC6A14 and SLC26A9 are robustly expressed in human lung epithelia, 
sweat gland, as well as intestinal epithelia as measured by RT-PCR (not shown). We 
anticipate that meconium ileus modifier genes may also influence early pathology in other 
CF-affected organs, and thus could provide important insights into the mechanisms of CF 
disease severity and co-morbidities.
These findings collectively have important practical implications for CF, where therapeutic 
strategies should consider pharmacologic modulation of epithelial function, in 
complementation with paradigms aimed at directly improving function or delivery of the 
mutated CFTR gene product to the apical membrane32.
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Pasterkamp,H., Children’s Hospital of Winnipeg, Winnipeg, Canada/Paterson,N., London 
Health Sciences Centre, London, Canada/Pedder,L., Chedoke-McMaster Hospital, 
Hamilton, Canada/Perkett,E., Vanderbilt University Medical Center, TN/Perrault,L., Centre 
de santé et des services sociaux de Rouyn-Noranda, Quebec, Canada/Perry,G., University of 
Kansas Medical Center, KS/Petit,N., Center Hospitalier Rouyn-Noranda, Rouyn-Noranda, 
Canada/Pian,M., University of California San Diego Children's Hospital, CA/Pineau,L., 
Grand River Hospital, Kitchener,Canada/Platzker,A., Children's Hospital of Los Angeles, 
CA/Popa,C., Centre de santé et des services sociaux de Rouyn-Noranda, Quebec, Canada/
Prestidge,C., Children's Medical Center of Dallas, TX/Price,A., London Health Sciences 
Centre, London, Canada/Rabin,H., Foothills Medical Centre, Calgary, Canada/Radford,P., 
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Phoenix Children's Hospital, AZ/Ratjen,F., The Hospital for Sick Children, Toronto, 
Canada/Regelmann,W., University of Minnesota, MN/Ren,C., University of Rochester 
Medical Center, Strong Memorial Hospital, NY/Repetto,G., Universidad del Desarrollo de 
Santiago, Chile/Retsch-Bogart,G., University of North Carolina at Chapel Hill, NC/
Richards,W., Memphis Lung Physicians, MS/Riva,M., Via-Christi, St. Francis Campus, KS/
Rivard,L., Centre hospitalier universitaire de Sherbrooke, Fleurimont, Sherbrook, Canada/
Roberts,D., Providence Medical Center, AK/Rock,M., University of Wisconsin Hospital, 
WI/Rosen,J., Albany Medical College, NY/Rowland,M., Our Lady’s Children’s Hospital, 
Ireland/Royall,J., Childrens Hospital of Oklahoma, OK/Rubenstein,R., Children's Hospital 
of Philadelphia, PA/Ruiz,F., University of Mississippi Med. Ctr., MS/Scanlin,T., Children's 
Hospital of Philadelphia, PA/Schechter,M., Emory University School of Medicine, GA/
Schmidt,H.J., Virginia Commonwealth University, VA/Schwartzman,M., Joe DiMaggio 
Children's Hospital, FL/Scott,P., Georgia Pediatric Pulmonology Assoc., PC, GA/Shay,G., 
Kaiser Permanente Medical Center, CA/Simon,R., University of Michigan Health System, 
MI/Smith,P., Long Island College Hospital, NY/Solomon,M., The Hospital for Sick 
Children, Toronto, Canada/Spencer,T., Children's Hospital of Boston, MA/Stecenko,A., 
Emory University, GA/Stokes,D., University of Tennessee, TN/Sullivan,B., Marshfield 
Clinic, WI/Taylor-Cousar,J., University of New Mexico, NM/Taylor,C., University of 
Sheffield, United Kingdom/Thomas,N., Pennsylvania State University College of Medicine, 
PA/Thompson,H., St. Luke's CF Clinic, ID/Toder,D., Children's Hospital of Michigan and 
Harper University Hospital, MI/Tullis,E., St.Michael’s Hospital, Toronto, Canada/
Turcios,N., University of Medicine & Dentistry of NJ, NJ/Van Biervliet,S., Ghent 
University Hospital, Belgium/van Wylick,R., Hotel Dieu Hospital, Kingston, Canada/
Varlotta,L., St. Christopher's Hospital for Children, PA/Vauthy,P., Toledo Children's 
Hospital, OH/Voynow,J., Duke University, NC/Wainwright,C., Royal Children's Hospital, 
Australia/Walker,P., St. Vincent’s Hospital - Manhattan, NY/Warren,W.S., Hershey 
Medical Center, PA/Waters,I., Royal Jubilee Hospital, Victoria, Canada/Wilmott,R., St. 
Louis University, MO/ Wilcox,P., St. Paul’s Hospital, Vancouver, Canada/Wilschanski,M., 
Hadassah Medical Organization, Israel/Wojtczak,H., Naval Medical Center - San Diego, 
CA/Yee,W., New England Medical Center, MA/Zacher,C., St. Alexius Heart & Lung CF 
Clinic, ND/Zanni,R., Monmouth Medical Center, NJ/Zeitlin,P., Johns Hopkins Hospital, 
MD/Zuberbuhler,P., University of Alberta Hospitals, Edmonton, Canada.
Contributing French CF Centers and Principal Investigators
Abely,M., American Memorial Hospital, Reims/Bassinet,L., Centre Hospitalier 
Intercommunal de Créteil, Créteil/Belleguic,C., Hôpital Pontchaillou, Rennes/Bellon,G., 
Hôpital Femme Mère Enfant, Bron/Bessaci,K., American Memorial Hospital, Reims/
Bonnel,A.S., Hôpital André Mignot, Le Chesnay/Bremont,F., Hôpital des Enfants de 
Toulouse, Toulouse/Brouard,J., Centre Hospitalier Universitaire de Caen, Caen/Bui,S., 
Hôpital Des Enfants Groupe Pellegrin, Bordeaux/Chiron,R., Hôpital Arnaud de Villeneuve, 
Montpellier/Chumbi-Flores,R., Hôpital de la Tronche, Grenoble/Dalphin,J.C., CNRS-UFC, 
UMR 6249 Chrono-environnement, Hôpital Jean Minjoz, Besançon/Dalphin,M.L., Centre 
Hospitalier Universitaire de Besançon, Besançon/David,V., Hôpital Mère-Enfant, Nantes/De 
Miranda,S., Hôpital Foch, Suresnes/Derelle,J., Hôpital d’Enfants, Vandoeuvre les Nancy/
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Domblides,P., Hôpital Haut Lévêque, Pessac/Dominique,S., Centre Hospitalier Universitaire 
Charles Nicolle, Rouen/Dubus,J.C., Hôpital d’Enfants de la Timone, Marseille/Durieu,I., 
UCBL1,Groupe Hospitalier Lyon Sud - Hospices Civils de Lyon, Pierre Bénite/Dury,S., 
Hôpital Maison Blanche, Reims/Ellafi,M., Centre Hospitalier Universitaire de Caen, Caen/
Epaud,R., Centre Hospitalier Intercommunal de Créteil, Créteil/Fanton,A., Hôpital 
d’Enfants du Bocage, Dijon/Fayon,M., Hôpital Des Enfants Groupe Pellegrin, Bordeaux/
Fleurence,E., Hôpital d’Enfants, Saint-Denis de la Réunion/Foucaud,P., Hôpital André 
Mignot, Le Chesnay/Ginies,J.L., Centre Hospitalier Universitaire d’Angers, Angers/
Godbert,B., Hôpital de Brabois, Vandoeuvre les Nancy/Grenet,D., Hôpital Foch, Suresnes/
Guillot,M., Centre Hospitalier Robert Bisson, Lisieux/Heraud,M. C., Centre Hospitalier 
Estaing, Clermont-Ferrand/Housset,B., Centre Hospitalier Intercommunal de Créteil, 
Créteil/Hubert,D., Hôpital Cochin, Paris/Huet,F., Hôpital d’Enfants du Bocage, Dijon/
Kessler,R., Hôpital Civil, Strasbourg/Labbé,A., Centre Hospitalier Estaing, Clermont-
Ferrand/Laurans,M., Centre Hospitalier Universitaire de Caen, Caen/Le Bourgeois,M., 
Necker Hôpital d’Enfants Malades, Paris/Le Roux,P., Hôpital Jacques Monod, 
Montivilliers/Llerena,C., Hôpital de la Tronche, Grenoble/Loeuille,G.A., Centre Hospitalier 
de Dunkerque, Dunkerque/Marguet,C., Centre Hospitalier Universitaire Charles Nicolle, 
Rouen/Melly,L., Hôpital Renée Sabran, Giens/Moisan-Petit,V., Centre Hospitalier Bretagne 
Atlantique, Vannes/Munck,A., Hôpital Robert Debré, Paris/Murris-Espin,M., Hôpital 
Larrey, Toulouse/Nove-Josserand,R., Groupe Hospitalier Lyon Sud - Hospices Civils de 
Lyon, Pierre Bénite/Pautard,J.C., Hôpital Nord, Amiens/Pin,I., INSERM U823 Université 
Joseph Fourier,Hôpital de la Tronche, Grenoble/Pramil,S., Centre Hospitalier Universitaire 
Charles Nicolle, Rouen/Prevota,A., Hôpital Calmette, Lille/Rames,C., Hôpital Nord, 
Amiens/Rault,G., Centre de Perharidy, Roscoff/Reix,P., Hôpital Femme Mère Enfant, Bron/
Remus,N., Centre Hospitalier Intercommunal de Créteil, Créteil/Renouil,M., Groupe 
Hospitalier Sud Réunion, Saint-Pierre de la Réunion/Reynaud-Gaubert,M., Hôpital Nord, 
Marseille/Richaud Thiriez,B., Hôpital Jean Minjoz, Besançon/Roussey,M., Université de 
Rennes 1, Hôpital Sud Annexe Pédiatrique, Rennes/Sermet-Gaudelus,I., Necker Hôpital 
d’Enfants Malades, Paris/Stremler,N., Hôpital d’Enfants de la Timone, Marseille/
Uffredi,M.L., Centre Hospitalier Bretagne Atlantique, Vannes/Urban,T., Centre Hospitalier 
Universitaire d’Angers, Angers/Vigneron,P., Centre Hospitalier Bretagne Sud, Lorient/
Wallaert,B., Hôpital Calmette, Lille/Weiss,L., Hôpital de Hautepierre, Strasbourg.
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Meconium Ileus GWAS identifies genome-wide significant SNPs. Association analysis was 
performed on all SNPs with minor allele frequencies > 2% that passed QC criteria (Online 
Methods).
(a) Genome-wide Manhattan plot for meconium ileus. The black solid line corresponds to 
the genome-wide significance threshold7 (P<5×10−8), and the black dashed line to the 
suggestive association threshold, expected once per genome scan (P 
<1/543,927=1.84×10−6). A total of five SNPs in two regions (SLC6A14 on chromosome X, 
and SLC26A9 on chromosome 1) have association evidence exceeding the genome-wide 
threshold. The SNPs, rs4077468 and rs4077469 are in perfect LD and appear as one SNP as 
they are separated by only 128bp.
(b) Regional plot for SLC26A9. LocusZoom viewer was used to display the association 
evidence around SLC26A9 based on NCBI Build 36/hg18. Symbol coloring reflects 
HapMap CEU LD r2 values with the most significant SNP. The significant SNPs, 
rs4077468, rs7419153 and rs12047830 (Table 2), occur 2.17 kb, 4.72 kb and 4.12 kb 
upstream, respectively, of the transcription start site. The significant SNP, rs7512462, occurs 
in intron 5. A gap occurs in the genomic sequence between the SLC26A9 and FAM72A 
genes in both NCBI36.3 and GRCh37 primary reference assemblies.
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(c) Regional plot for SLC6A14. The association evidence around SLC6A14 was displayed as 
above. Rs3788766 (Table 2) is positioned 0.95 kb upstream of the transcription start site and 
is within the binding site of the CEBPB transcription factor as annotated by ENCODE33 (not 
shown). The mRNA transcript corresponding to CXorf61 is downstream (3’) of SLC6A14.
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The apical membrane hypothesis identifies genes associated with meconium ileus. A list of 
157 genes was annotated using the AmiGO tool13 (version 1.7; March 28, 2010) based on 
the Gene Ontology data14 (GO:00163245) using the cell location search phrase “apical 
plasma membrane” with restriction to Homo sapiens. In total, 3,814 GWAS SNPs are within 
±10 kb of the boundaries of 155 genes (NCBI36/hg18). Two genes were not tagged by any 
of the GWAS SNPs; SLC6A14 was not annotated to the apical plasma membrane.
(a) QQ-plot of the apical SNPs in the discovery sample. The observed association statistics 
(red), and the statistics calculated from the 10,000 phenotype-permutated replicates are 
shown (light gray).
(b) Statistical significance of the apical membrane hypothesis in the discovery sample. 
Statistical significance (permutation P = 0.0002) was established via a sum statistic, 
summing the association evidence (Wald χ21 statistic) over all the 3,814 SNPs with the 
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observed sum statistic displayed as a vertical line (red), and the 10,000 permutation-based 
sum statistics displayed as a histogram (light gray).
(c) QQ-plot of the apical SNPs in the replication sample. The SNPs in the French replication 
cohort were required to have MAF > 6% because of the reduced sample size (1232 × 6% ≈ 
3763 × 2%). In total 3,420 GWAS SNPs are within ±10 kb of the boundaries of 154 apical 
genes.
(d) Statistical significance of the apical membrane hypothesis in the French replication 
sample (permutation P=22/1,000=0.022).
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Assessment of the nuclear envelope null hypothesis. A list of 231 genes was generated from 
the nuclear envelope as defined by GO annotation (GO:0005635) similarly as for the apical 
membrane list. In total, 3,537 GWAS SNPs are within ±10 kb of the boundaries of 224 
tagged genes (NCBI36/hg18). A priori, the nuclear envelope list should not contain genes 
associated with meconium ileus (under the null of no association).
(a) QQ-plot of the nuclear envelope gene SNPs in the discovery sample.
(b) Statistical significance of the nuclear envelope hypothesis in the discovery sample. 
Statistical evaluation indicates that genes listed in the nuclear envelope are, as expected, not 
significantly associated with meconium ileus (permutation P=4639/10,000=0.4639).
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